retatrutide nonalcoholic fatty liver disease trial nash A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Liver Fibrosis PDF) Triple hormone receptor agonist

Were already seeing changes in bariatric surgery volumes, but what procedures are going to become more relevant

These regulatory processes can be disrupted following surgery, which can lead to altered glucose metabolism

This dual oversight reduces cardiovascular risk

It sounds a cautionary note for short-term use without a more comprehensive approach to weight management. Overeating far more likely Adam Collins, associate professor of nutrition at the University of Surrey in England, who was not involved in the study, called the paper timely and important. Collins underlined that weight regain is a common issue in all weight loss interventions, but the paper shows that this problem is amplified with GLP-1 medications

It means the quality assurance framework differs from brand-name manufacturing

BMC Pregnancy and Childbirth, 24, 720